Kewaunee Scientific reported record revenue of $282 million for fiscal 2026, a nearly 14% compound annual growth rate since fiscal 2021, and outlined investments for fiscal 2027. EBITDA totaled $22.4 million, and the company reduced long-term debt by approximately $20 million, fully repaying the NuAire seller note. Lab Products Group sales rose 19.8% to $214.9 million, while international sales increased 9.9% to $67.1 million. Consolidated backlog declined to $165.9 million from $214.6 million after major international projects were completed. For fiscal 2027, the company plans to invest in product innovation, manufacturing capacity and efficiency, global expansion, and disciplined acquisitions, while continuing infrastructure and compliance upgrades.
Kewaunee Scientific CorporationRecord revenue and EBITDA, debt reduction, and growth investments for fiscal 2027.
